Multiple sclerosis (MS) affects nearly 400 000 people
in the United States and over 2.5 million people worldwide.
Its presentation and course are highly variable
and often unpredictable, and the diagnostic criteria
for MS continue to evolve, reflecting ongoing
advancements in neuroimaging and neuroimmunology.
The effects of MS can be devastating, and it
remains the most common disabling neurologic condition
in young adults.
Managed care pharmacists play a key role in the
management of patients with MS, educating patients
and fellow clinicians, and monitoring therapeutic efficacy
while screening for potential adverse effects. In
addition, the managed care pharmacist must make difficult
and often complex decisions regarding the
effects of MS and its treatment on health systems, managed
care plans, and large patient groups.
This educational activity will provide managed care
pharmacists with a thorough and timely update,
including practical strategies for translating the latest
medical and scientific developments into the best possible
patient outcomes and unique perspectives in the
managed care setting.
To provide pharmacists working in managed care,
Veterans Affairs, and Department of Defense settings with
clinical updates to improve neuroprotection, evaluate how
to utilize imaging modalities to observe the clinical and
immunological effects of disease-modifying therapies on
the pathology of multiple sclerosis, and design and implement
strategies to improve patient adherence to therapy.
This activity is designed for managed care, Veterans Affairs, and Department of Defense pharmacists. No prerequisites required.
Upon the conclusion of this activity, the participant should be able to:
- Describe the pathophysiology and the biology of demyelination, axonal degeneration, and
neuronal cell death in multiple sclerosis (MS).
- Explain the potential role current and future immunomodulatory therapies have in
promoting neuroprotection and neuroregeneration.
- Evaluate the long-term safety and efficacy of available immune-modulating MS agents and
methods used to monitor the effectiveness of MS therapies.
- Identify issues regarding the management of MS in managed care.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CE activity.
The estimated time to complete this educational activity: 1.5 hours.
Release date: September 15, 2009. Expiration date: September 15, 2011.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.
Credit Designation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based educational activity will provide 1.5 contact
hours credit (0.15 CEUs).
Successful completion includes participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination one more time. ACPE Program #064-000-09-205-L01-P.
Jacquelyn Bainbridge, PharmD, FCCP (Chair)
Department of Clinical Pharmacy/Department of Neurology
University of Colorado Denver
Jeffrey L. Bennett, MD, PhD
Departments of Neurology and Ophthalmology
University of Colorado Denver School of Medicine
Melody Ryan, PharmD, MPH, BCPS, CGP
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Department of Neurology
University of Kentucky College of Medicine
Ellen Whipple Guthrie, PharmD
Clinical Assistant Professor
University of Georgia College of Pharmacy
Children’s Healthcare of Atlanta at Egleston
Sheldon J. Rich, RPh, PhD
President, SJR Associates, LLC
Palm Beach Gardens, FL
Clinical Assistant Professor, University of Michigan
Ann Arbor, MI
Adjunct Assistant Professor, Wayne State University
Policy on Faculty and Provider Disclosure
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.